Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients

Authors

  • Rena Arusita Maranatha1 , Laksmi Wulandari2 , Gatot Soegiarto3

DOI:

https://doi.org/10.37506/ijfmt.v15i1.13423

Keywords:

NSCLC, EGFR mutation, tyrosine kinase inhibitor, uncommon, common.

Abstract

Objective: To compare the response of first-generation EGFR-TKI (epidermal growth factor receptortyrosine kinase inhibitors) in non-small cell lung cancer (NSCLC) patients with single common and
uncommon EGFR mutation.
Methods: Patients were divided into two groups, the uncommon (exon 21 L861Q, exon 18 G719X, exon
18 delE709) and common EGFR mutation group (exon 19 deletion, exon 21 L858R). Health-related quality
of life (HRQOL) using EuroQol EQ-5D® questionnaire, body weight, performance status (PS), Response
Evaluation Criteria in Solid Tumors (RECIST) on chest CT, progression-free survival (PFS) and overall
survival (OS) was recorded during TKI therapy.
Results: The value of HRQOL was stable and PS was constant in both groups, body weight was constant
in uncommon group (42.1%) and increased in common group (44.1%; p=0.165). The uncommon group
showed mostly progressive disease in RECIST (47.4%) while the common group showed mostly partial
response (42.2%; p=0.007). PFS in the uncommon group was 4 (2.0-6.0) months and 7.0 (2.0-21.0) months
in the common group (p=0.001). OS in the uncommon and common group were 4.00±1.71 months and
10.00±6.94 months (p<0.001), respectively.
Conclusion: NSCLC patients with common EGFR mutations showed a better response and survival rate
compared to uncommon EGFR mutations on first-generation TKI therapy.

Author Biography

Rena Arusita Maranatha1 , Laksmi Wulandari2 , Gatot Soegiarto3

1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga-Dr.
Soetomo General Academic Hospital, Surabaya 60286, Indonesia, 2
Thoracic Oncology Division, Department
of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General
Academic Hospital, Surabaya 60286, Indonesia, 3
Clinical Immunology Division, Department of Internal Medicine,
Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia

Published

2020-12-31

How to Cite

Rena Arusita Maranatha1 , Laksmi Wulandari2 , Gatot Soegiarto3. (2020). Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients. Indian Journal of Forensic Medicine & Toxicology, 15(1), 302-308. https://doi.org/10.37506/ijfmt.v15i1.13423

Issue

Vol. 15 No. 1 (2021): Indian Journal of Forensic Medicine & Toxicology

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details

https://creativecommons.org/licenses/

CC BY

This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.

  1. The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
  1. The journal allows the author(s) to hold the copyright without restrictions.
  1. The journal allows the author(s) to retain publishing rights without restrictions